CHRISTINA M. MARRA
HIV can directly infect the cerebrospinal fluid (CSF) and the brain. Infection of the CSF is a notable feature of the acute retroviral syndrome, and CSF pleocytosis is common in HIV infection, particularly among individuals with high peripheral blood CD4+ T-cell counts, detectable plasma HIV RNA, and in those not on antiretroviral therapy (1). Infection of the brain likely is the substrate for dementia in HIV infection. The immunodeficiency caused by HIV predisposes individuals to secondary or opportunistic central nervous system (CNS) infections or neoplasms (Table 19.1). The incidence of dementia and most CNS opportunistic infections has declined in the developed world with widespread use of combination antiretroviral therapy (CART). However, although the incidence may be decreasing, the prevalence of cognitive impairment is increasing (2–4). In addition, treatment of HIV itself may be associated with neurologic complications. The clinical findings and treatment of CNS opportunistic infections seen in HIV-infected individuals are covered in several chapters of this book. In particular, a detailed discussion of cerebral toxoplasmosis is provided in Chapter 43, and neurosyphilis is covered in Chapter 38. This chapter addresses two opportunistic infections not covered elsewhere: primary CNS lymphoma, which is considered with infections because of its association with Epstein-Barr virus infection, and progressive multifocal leukoencephalopathy (PML) caused by the JC virus. In addition, the most common CNS complications associated with HIV itself are discussed, including newly recognized syndromes.
FOCAL BRAIN DISEASE
Opportunistic infections, neoplasms, and cerebrovascular disease are the most common causes of focal findings referable to the brain in HIV-infected patients. In such individuals, the presence or absence of contrast enhancement and mass effect on cranial neuroimaging studies helps to narrow the differential diagnosis. Lesions associated with contrast enhancement and mass effect are most commonly due to toxoplasmosis, primary CNS lymphoma, or tuberculoma. Lesions with minimal or no contrast enhancement and no mass effect are most commonly due to PML.
Primary Central Nervous System Lymphoma
Etiology
Primary CNS lymphomas in HIV-infected patients are typically of B-cell origin and are classified as diffuse large cell or immunoblastic (5). Epstein-Barr virus (EBV) is detectable in these tumors in virtually all HIV-infected patients (5). Prolonged immune suppression and EBV-induced B-cell stimulation likely contribute to tumor development (6).
Differential Diagnosis
As noted earlier, the most common causes of brain lesions associated with contrast enhancement and mass effect are toxoplasmosis, primary CNS lymphoma, and tuberculoma. Other causes are listed in Table 19.1.
Clinical Symptoms and Findings
The presenting clinical features of HIV-associated primary CNS lymphoma include confusion, lethargy, memory loss, hemiparesis, speech and language disorders, seizures, and cranial nerve palsies (7,8).
Laboratory and Imaging Studies
HIV-infected patients with primary CNS lymphoma typically have peripheral blood CD4+ T-cell counts less than 50/µL (9). Brain computed tomography (CT) or magnetic resonance imaging (MRI) show ring- or homogeneously enhancing lesion(s), often located periventricularly or in the frontal lobes, although other locations may be seen (Fig. 19.1). These lesions may cross the midline in the corpus callosum and may be associated with patchy nodular ventricular enhancement (10). Thallium-201 (201Tl) single-photon emission computed tomography (SPECT) may be helpful in distinguishing between CNS infections and primary CNS lymphoma in HIV-infected individuals. Focal areas of increased 201Tl uptake are seen in patients with lymphoma, whereas no brain uptake is seen in patients with CNS infections such as Toxoplasma encephalitis or tuberculoma (11,12). Delayed imaging and calculation of a retention index increase the specificity of the test (12).
Although the diagnosis of primary CNS lymphoma can only be proven by histopathology, examination of CSF for EBV DNA by polymerase chain reaction (PCR) may be sensitive and specific for establishing the diagnosis (13) when it is used in the appropriate clinical setting: an HIV-infected patient with a focal brain lesion with mass effect and enhancement. The positive predictive value of the test is highest in patients with a low likelihood of CNS toxoplasmosis, such as those who are Toxoplasma seronegative or who have been taking trimethoprim-sulfamethoxazole for prophylaxis against toxoplasmosis. When the test is used more broadly in clinical settings, the positive predictive value of detection of EBV DNA in CSF is lower (14,15).
Treatment and Prevention
HIV-associated primary CNS lymphomas are sensitive to radiation therapy. In a retrospective analysis conducted before the availability of CART, median survival was about 3 to 4 months with radiation therapy and dexamethasone and untreated survival was 3 to 4 weeks (16). Death was usually due to opportunistic infection rather than lymphoma (7,8). Absence of opportunistic infection, younger age, higher Karnofsky performance status, and delivery of higher biologically effective doses of radiation were associated with longer survival (17).
More modern studies show that whole brain radiation therapy (at least 30 Gy) (18–20) and CART (18,20,21) are associated with better survival in HIV-infected patients with primary CNS lymphoma, often with best survival seen in those who receive both modalities. Prolonged survival has also been reported in HIV-infected patients with primary CNS lymphoma who only received CART (22–24). Some have suggested that whole brain radiation be reserved for patients who do not respond to antiretrovirals to avoid the morbidity, particularly leukoencephalopathy, associated with this treatment modality. Because of the association with EBV, some investigators have advocated combination therapy for HIV-associated primary CNS lymphoma that targets this virus with agents such as ganciclovir or foscarnet. Individual reports of success with these regimens can be difficult to evaluate because patients are often also treated with radiation, CART, and immune modulators (25–30). Overall, treatment data for HIV-associated primary CNS lymphoma are mostly from retrospective case reports and series and are limited by selection bias. The best treatment for HIV-associated primary CNS lymphoma is not known because a randomized trial has not been conducted, and, given the low incidence of the disorder, may never be feasible.
Prior to the advent of CART, primary CNS lymphoma occurred in 1% to 4% of HIV-infected persons. Since CART has become widely available, the incidence of this disorder has declined (31,32) and survival has improved (18,33). Thus, prevention lies in antiretroviral treatment to prevent prolonged immunosuppression.
Progressive Multifocal Leukoencephalopathy
Etiology
PML is caused by a polyoma virus called JC virus. This virus is usually acquired in childhood. It remains latent in kidney and perhaps in brain, reactivates in the setting of immunosuppression, and infects oligodendrocytes and less so astrocytes. Death of oligodendrocytes leads to demyelination.
Differential Diagnosis
The diagnosis of PML should be considered in patients with dementia, particularly if there are also focal neurologic findings. Varicella-zoster encephalitis may cause demyelination and should also be considered (34). Cytomegalovirus (CMV) encephalitis is sometimes accompanied by focal lesions that could mimic PML (35). Substance abuse, particularly a form of heroin use called “chasing the dragon,” can cause clinical and radiographic abnormalities similar to PML (36). A severe form of HIV-associated leukoencephalopathy characterized pathologically by extensive perivascular macrophage infiltration and demyelination and high levels of brain and CSF HIV RNA has been described (37). Patchy or confluent white matter high signal intensity is seen on brain MRI. The syndrome occurs in patients failing CART and is accompanied by cognitive abnormalities. Leukoencephalopathy has been described in individuals whose HIV is successfully treated, and has been attributed both to “CNS immune reconstitution” (38–40) and to “CNS escape” in individuals with suppressed plasma HIV RNA but detectable CSF HIV RNA (41). The latter two diagnoses may be distinguished from PML because they may be associated with CSF pleocytosis.
Clinical Findings
Patients with PML typically experience insidious onset of progressive neurologic deficits, most commonly cognitive dysfunction, limb weakness, gait disturbance, coordination difficulties, and visual loss. Headache is a complaint in about one fourth of patients. Neurologic examination shows focal deficits, particularly hemiparesis or visual field abnormalities (42,43). Less common manifestations of CNS JC infection include cerebellar granule cell neuronopathy (44) and JC infection of cortical pyramidal neurons, causing an acute encephalopathy (45).
Laboratory and Imaging Studies
HIV-infected patients with PML typically have peripheral blood CD4+ T cells less than 200/µL, although even before the advent of CART, about 10% of patients had CD4 counts above this threshold (43). In the current treatment era, individuals with PML and much higher or even near-normal peripheral blood CD4+ T cell concentrations have been reported (46,47).
Brain CT in patients with PML may sometimes be normal. More often, it shows multiple, often confluent, white matter lesions that are most commonly located in the parietooccipital regions. These lesions are low density and have little, if any, mass effect (43). Enhancement may be seen in 10% of CT scans and is usually faint and peripheral (43). Brain MRI shows more lesions than CT (48). In contrast to the white matter lesions seen in HIV-associated dementia, which are visible only on T2-weighted images, PML lesions are low intensity on T1-weighted and high intensity on T2-weighted images (Fig. 19.2); about 15% show faint contrast enhancement (43). Contrast enhancement is more likely to be seen in the setting of immune reconstitution (see the following discussion). In addition to the abnormalities seen on T1- and T2-weighted MRI, restricted diffusion may be seen; additional examples of MRI abnormalities in PML are shown in Chapter 3.
Diagnostic criteria for PML have been recently published (49). In patients with characteristic clinical and neuroimaging findings, histologic examination or identification of JC virus DNA by PCR in CSF can confirm the diagnosis. However, a negative PCR does not exclude the diagnosis. Individuals who develop PML while receiving CART as well as those with higher peripheral blood CD4+ T cell concentrations are more likely to have a negative diagnostic PCR (50).
Treatment and Prevention
Recent studies suggest that the current incidence of PML has declined approximately three- to fourfold compared to before 1996, with estimates among HIV-infected individuals ranging from 0.6 to 1.3 per 1,000 person-years (51,52). Treatment with potent antiretrovirals has also resulted in significantly improved survival in patients with PML (51–53).
Several prognostic factors have been identified in HIV-associated PML. Mass effect on MRI (54) and brainstem and cerebellar involvement (55,56) are associated with poorer outcome. Higher peripheral blood CD4+ T-cell count at diagnosis (48,51,57–60), PML as the AIDS-defining illness (58), lower concentration and decline in CSF JC virus DNA concentration during antiretroviral therapy (59–64), and the presence of JC virus-specific cytotoxic T cells in blood (65–67) are associated with improved survival.
All HIV-infected patients with PML should be treated with CART aimed at complete suppression of plasma HIV viremia. Whether certain types of antiretroviral regimens are more effective than others remains a matter of debate because few prospective studies have been conducted. Two retrospective analyses suggest that a regimen that includes a protease inhibitor may be more effective than one that does not (68,69). Gasnault and colleagues (60) conducted a multicenter, prospective, open-label trial of an individualized regimen of five antiretrovirals, including enfuvirtide for the first 6 months, in 28 HIV-infected patients with PML. The 1-year survival was 75%, significantly higher than the historically reported survival of 45% at the time the trial was planned (63,70–72). In this trial, all deaths occurred within the first 4 months of treatment (60).
As a consequence of an immune reconstitution inflammatory syndrome (IRIS), PML may develop (unmasking or simultaneous IRIS) or worsen (paradoxical or delayed IRIS) after beginning antiretroviral therapy. In an observational study in Spain of 61 patients with PML, 14 (23%) developed PML IRIS, of which 8 were unmasking IRIS and 6 paradoxical IRIS (53). In a case series and retrospective review, PML IRIS developed 1 week to 26 months (median 7 months) after beginning antiretroviral therapy, with a shorter latency, greater number of MRI-defined brain lesions, and poorer outcome in paradoxical compared to unmasking IRIS (73). A retrospective case series showed that peripheral blood CD4+ T cells & <50/µL at the time of initiating antiretroviral therapy significantly increases the risk of PML IRIS and that the prognosis of patients with PML IRIS is no different than PML patients without IRIS (74).
Paradoxical IRIS is characterized by clinical worsening and progression of previously defined MRI lesions or development of new lesions, often, but not always, with evidence of contrast enhancement. In the absence of new enhancement, paradoxical IRIS can be difficult to distinguish from progressive disease, although the onset of clinical worsening in IRIS may be more acute. Both fatal and benign courses have been described (73,75–77) as well as individuals that do and do not respond to immunosuppression with steroids (73,78). A single case of rapid improvement in paradoxical PML IRIS after treatment with the CCR5 inhibitor, maraviroc, but not treatment with methylprednisolone, has been reported (79). The authors speculated that blocking of CCR5+ leukocyte recruitment to the CNS might have been the underlying mechanism of improvement.
No specific therapy for HIV-associated (or nonassociated) PML has been identified. Cytosine arabinoside (Ara-C) given intravenously (IV) or intrathecally did not confer a survival benefit in a clinical trial conducted before the availability of CART (80). A metaanalysis of cidofovir showed no benefit beyond that of CART (72). Mefloquine showed anti-JC activity in an in vitro assay (81), but an open-label randomized trial was stopped early because of lack of efficacy (64). Based on the observation that the cellular receptor for JC virus is the 5-HT2A serotonin receptor (82), mirtazapine has been used for PML treatment with anecdotal reports of success (83,84), but no clinical trial has been conducted.
HIV-infected patients with PML who survive generally have persistent neurologic deficits, although some regain independence. In the trial by Gasnault and colleagues referenced earlier, the median modified Rankin scale at 12 months in the 21 survivors was 3 (moderate disability). Eight patients had only slight disability and were independent (60). In contrast, in the Swiss HIV Cohort Study, among 47 individuals who survived more than 1 year, only 8 (17%) had clinical improvement (52). In a convenience sample of 23 HIV-infected patients with PML who survived at least 5 years, 9 remained neurologically stable, 10 had partial improvement, and 4 had marked improvement; 8 had only slight disability and lived independently (55). In a population-based study from Denmark, 5 of 11 patients followed for 3 years (from an original group of 47 patients) returned to their pre-PML level of function (51).
DIFFUSE CENTRAL NERVOUS SYSTEM DISEASE
HIV-Associated Neurocognitive Disorders
Cognitive impairment due to HIV infection was first characterized by Navia et al. (85) in 1986 and termed AIDS dementia complex or ADC to emphasize a triad of cognitive, motor, and behavioral abnormalities: (a) forgetfulness and loss of concentration; (b) apathy, social withdrawal, and irritability; and (c) loss of balance and leg weakness. On neurologic examination, such patients typically demonstrated slowed verbal and motor responses, reminiscent of neurologic findings in Parkinson disease. Not every patient with ADC had all three components of the triad at onset of disease, and not all patients with mild disease progressed to more severe disease. As will be discussed further in the following section, with the advent of CART, the incidence of HIV-associated dementia (HAD) has decreased, but the incidence and prevalence of less severe forms of cognitive impairment have increased. In 2006, a working group addressed the criteria for diagnosis of HIV-associated neurocognitive disorders (HAND) (86). These criteria are commonly referred to as the “Frascati criteria,” because the working group met in Frascati, Italy. Three categories of impairment were established: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HAD. The diagnosis of all three disorders is based on results of neuropsychologic (NP) tests covering at least the domains of verbal/language, attention/working memory, abstraction/executive, memory (learning, recall), speed of information processing, and sensory–perceptual or motor skills, in combination with an assessment of everyday functioning. In all categories, cognitive or functional impairment cannot be explained by delirium, opportunistic CNS disease, systemic illness, psychiatric illness, substance use, or medications with CNS effects (Table 19.2). Although these categories were intended for research purposes, they have become increasingly applied to clinical settings.
Epidemiology and Risks
Estimates early in the HIV epidemic suggested that at least 60% of patients with AIDS developed overt or subclinical HAD (85,87). The proportion decreased to about 7% in the first years after antiretrovirals became available (88,89). Several studies in the CART era show that the prevalence of HAD is low but the prevalence of milder impairment (MND and ANI) is surprisingly high. For example, in the multicenter U.S. CNS HIV Antiretroviral Therapy Effects Research (CHARTER) study, among 1,316 participants without severe confounding disorders that could independently explain cognitive impairment, 2% had dementia, 12% had MND, and 33% had ANI (90). In a study of 100 Italian patients with undetectable plasma HIV RNA, 2% met criteria for HAD, 17% for MND, and 50% for ANI (91), and in a study of 400 French patients, 7% had HAD, 31% had MND, and 21% had ANI (92). Although symptomatic HAND (MND and HAD) remains a risk factor for poorer survival (4), the relevance of an ANI diagnosis has been questioned for several reasons. These include concerns that (a) normative NP data are from nonconfounded “normal” individuals rather than background-matched controls; (b) in a normally distributed population, 16% will score 1 SD below the norm on a given test; and (c) no published study has demonstrated that ANI confers a risk for subsequent dementia (93,94). In addition, patients frequently transition from mild impairment to normal cognition and vice versa despite stable CART regimens (95,96). Whether this reflects diagnostic imprecision, practice effects or normal variation remains undefined (97).
Low current, and in particular low nadir, CD4 is a risk factor for prevalent neurocognitive impairment in the CART era (90,95,98,99). However, the association between HIV-related factors and incident cognitive impairment is less clear. Although current but not nadir CD4 remained a significant predictor of incident dementia in the Concerted Action on Seroconversion to AIDS and Death in Europe (CASCADE) cohort (100), in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) study, neither current nor nadir CD4 or plasma HIV RNA predicted incident cognitive impairment (95). In a population-based study of 1,320 HIV-infected patients in Canada, incident symptomatic cognitive impairment was more common with lower nadir CD4 and plasma HIV RNA greater than 1 million copies/mL (101). In this study and in the CASCADE study, longer estimated duration of HIV infection conferred greater risk of incident impairment (100,101).
Etiology
HIV can be recovered from CSF (102) or brain (103) early in the course of infection, and acute meningitis or encephalitis may be part of the acute retroviral syndrome (102,104,105). Moreover, brain inflammation and injury is evident in primary HIV infection in some, but not all, patients (106–108). Most experts agree that productive brain HIV infection is restricted to perivascular macrophages and less so microglia (109). Infection of the CNS may be driven by activation of peripheral monocytes as a consequence of microbial translocation from the gut early in infection (110). Activated monocytes are better able to support productive HIV infection (111), and HIV DNA concentration in activated monocytes is higher in patients with cognitive impairment than in those with normal cognition (112). Astrocytes may be infected but do not support viral replication (113). The prevailing view is that HIV causes brain injury and subsequent cognitive impairment via indirect mechanisms (114–116). Proposed models suggest that HIV-infected mononuclear phagocytes release toxic viral gene products such as gp120 or tat. Alternatively, infected brain macrophages or microglia may release cell-derived toxins such as quinolinic acid; cytokines, including tumor necrosis factor-α (TNF-α); eicosanoids; platelet-activating factor; or nitric oxide. This hypothesis is particularly compelling because the neuropathology of HAD is characterized by increased numbers of activated macrophages, and the severity of dementia correlates better with the degree of macrophage staining in brain than with the number of HIV-infected cells in brain (117). Toxic substances released by activated macrophages may injure neurons directly, may injure astrocytes or oligodendrocytes and interfere with their supporting functions, or may stimulate astrocytes or oligodendrocytes to release toxic products that may augment neurotoxicity. Nonproductive HIV infection of astrocytes may contribute to macrophage activation, a 180 augmenting neurotoxicity.
The relationship between brain HIV infection and clinically evident cognitive impairment may be changing in the current treatment era, particularly among patients with mild impairment. A recent pathologic study of 589 individuals with advanced disease showed no relationship between brain HIV infection and HAND (118), and, as discussed in the following section, although detectable CSF HIV was associated with prevalent dementia and predicted it in the pre-CART era, these associations are less robust in the era of CART. Moreover, the relationship between lower nadir CD4 and cognitive impairment suggests that CNS injury may have occurred in the past, and that although impairment may be persistent, it may not reflect the effect of ongoing CNS infection, inflammation, or injury. This “legacy,” however, might lessen cognitive reserve. As HIV-infected patients live longer, aging (119), vascular disease (120–122), metabolic abnormalities (123), and CART toxicities (124–126) may increasingly contribute to cognitive impairment.
Differential Diagnosis
Before the advent of highly active antiretroviral therapy, HAD was a disease of those with advanced immunosuppression, and CMV encephalitis was an important alternative diagnosis to consider. In the current treatment era, patients with HAD may present with peripheral blood CD4+ T cells more than 200 cells/µL (2,3) and CMV encephalitis is rare. The differential diagnosis includes psychiatric disease, particularly depression; adverse effects from prescription or illicit drugs; and cerebral opportunistic infections including toxoplasmosis, tuberculosis, cryptococcal meningitis, and neurosyphilis. Rarely, PML may present solely with cognitive changes, but focal neurologic findings and neuroimaging almost always distinguish patients with PML from those with HAD (127).
Clinical Symptoms and Findings
Patients with HAD generally present with subacute onset of cognitive impairment, often with complaints of mental and physical slowness. Neurologic examination typically is remarkable for slowed verbal and motor responses. Ataxia and hyperreflexia may also be seen. A staging system for HAD has been used to characterize clinical severity (128,129). It is based on functional disability and ranges from normal cognitive and motor function (stage 0), to mild impairment (stage 1) with preserved ability to perform all but the more demanding tasks of work or daily activities, to end-stage disease (stage 4) distinguished by rudimentary comprehension and responses. Not all patients with mild disease progress to more severe stages.
Laboratory and Imaging Studies
The diagnosis of HAD is based on clinical findings and remains one of exclusion. There is no specific test that establishes the diagnosis. However, CSF studies may be the most informative. Conventional CSF evaluation helps exclude other disorders. Data from the Multicenter AIDS Cohort Study suggest that a CSF β2-microglobulin concentration more than 3.8 mg/dL in a CSF specimen with a normal white blood cell (WBC) count is specific, but not sensitive, for the diagnosis of HAD (130). In the pre-CART era, among patients with AIDS, CSF HIV RNA levels were elevated in those with cognitive impairment (131); they correlated with severity of dementia (132,133) and predicted incident impairment (134). In the CART era, CSF HIV RNA does not distinguish between those with and without cognitive impairment (135,136). However, in the clinical setting, measurement of CSF HIV RNA can be useful. A CSF concentration higher than plasma suggests, but does not prove, that cognitive impairment is due to ongoing CNS HIV infection and is one definition of CNS escape (see the following discussions).
Neuroimaging is useful in excluding other disorders but does not establish the diagnosis of HAD. Cranial CT may be normal or show atrophy or patchy white matter attenuation (85). Cranial MRI is more sensitive than CT for demonstrating white matter abnormalities and may show high T2 signal in the periventricular regions and in the centrum semiovale that are not seen on T1-weighted sequences (Fig. 19.3). However, atrophy and focal white matter abnormalities may be seen in HIV-infected individuals without cognitive changes (137).
Treatment and Prevention
Early studies showed that even zidovudine monotherapy improved cognition and survival in patients with HAD (138,139). Studies early in the CART era showed that decline in CSF HIV RNA and improvement in NP test performance could be seen in individuals treated with CART (140–142), and CART is also associated with increased survival in patients with HAD (143). Improvement in cognition after starting CART may lag behind improvement in CD4 or decline in plasma HIV RNA; in one study, improvement peaked at 24 to 36 weeks after beginning CART (144). That CART may also play a role in preventing development of cognitive impairment is shown by a recent study demonstrating that HIV-infected patients who initiated CART early in the course of disease had a low prevalence of cognitive impairment that was comparable to matched HIV-uninfected individuals (145).
In the last few years, much attention has been given to whether antiretroviral regimens with “good CNS penetration” are more effective in decreasing CSF HIV RNA concentration and in improving cognitive function than regimens with “poorer” penetration. Letendre and colleagues (146,147) have published two versions of the CNS Penetration Effectiveness (CPE) rank, which estimates CNS drug penetration based on virologic and pharmacologic data. The most recent version uses four categories (1–4), with higher values assigned to drugs with better predicted penetration (147). The score for a given regimen is calculated as the sum of the scores of its component drugs. Higher CPE regimens convey increased likelihood of suppressed CSF HIV RNA (146,147). However, the relationship between regimen CPE and improvement in cognition is less clear. Although several studies suggest that regimens with higher CPE improve cognitive function more than regimens with lower scores, this finding is not universal (148). A recent study suggested that the revised CPE rank is superior to the original, which might explain some, but not all, discrepancies between different studies (149). An observational study showed that higher CPE conveyed an increased risk of cognitive worsening in patients with advanced HIV (124), and a small randomized trial of three CART regimens showed that although patients in the arm with the highest CPE had greater cognitive improvement, these patients also had greater evidence of brain inflammation by neuroimaging (150).
Shikuma and colleagues (151) have proposed a monocyte efficacy (ME) score as a means of determining the effectiveness of an antiretroviral regimen in treating CNS HIV infection. The ME score is defined as the summed reciprocal (× 1,000) of each agent’s median effective concentration (EC50) in a resting macrophage acute infection model (151). The relationship between cognitive impairment and ME score was examined in a cohort of 139 individuals on stable CART for at least 6 months; those who were taking atazanavir or lopinavir were excluded because of lack of EC50 data. Patients whose regimens had higher ME scores had lower odds of symptomatic cognitive impairment. Of note, the CPE rank and ME score of individual regimens may not be congruent. For example, an “acceptable” regimen of abacavir, lamivudine, and nevirapine yields a high CPE of 9 but a low ME of 73 (152).
Several adjunctive agents have been investigated for the treatment of HAD. Their rationale is based on data reviewed above suggesting that neuronal damage is a downstream event triggered by release of toxic viral gene products or inflammatory mediators from infected mononuclear cells. None have proved to be beneficial, including nimodipine (153), CPI-1189 (an antioxidant that blocks TNF-α in animal models) (154), selegiline (155,156), memantine (157,158), minocycline (159–161), and rivastigmine (162).
Encephalitis in the Setting of Combination Antiretroviral Therapy: Central Nervous System Immune Reconstitution Inflammatory Syndrome, Central Nervous System Escape, and CD8+ T-Cell Encephalitis
Just as there are reports of IRIS in patients with CNS opportunistic infections treated with CART, “CNS IRIS” due to HIV itself has been reported after CART initiation (38–40). Typically, patients develop diffuse or focal neurologic symptoms and signs usually accompanied by CSF pleocytosis in the absence of an identifiable infectious agent. Such patients need to be distinguished from those with CNS escape in the setting of apparently effective CART. These patients develop diffuse or focal neurologic symptoms while on CART, with detectable CSF HIV RNA in the setting of suppressed peripheral viremia or with CSF HIV RNA concentrations higher than simultaneous plasma levels (163–165). Canestri and colleagues (166) described CNS escape in 11 patients defined as CSF HIV RNA more than 200 copies/mL with corresponding plasma HIV RNA less than 50 copies/mL or CSF HIV RNA more than 1 log higher than plasma. Clinical syndromes included meningitis, encephalitis, and myelitis. Based on genotypic analysis, CSF virus was not sensitive to the CART regimen in five patients (166). Asymptomatic low-level CNS escape with CSF HIV RNA concentrations ranging from 52 to 860 copies/mL has been described in a small series of patients (167). Compared to patients with undetectable CSF HIV RNA, those with CNS escape had a longer duration of CART and had experienced more treatment interruptions, raising the question of whether CSF viral “blips,” similar to what has been described in plasma, may occur. A review of the literature shows overlap between CNS IRIS and CNS escape. The distinguishing feature should be detection of CSF HIV RNA, which is not seen in IRIS, but that is an integral part of the diagnosis of CNS escape. Reports describe successful treatment of CNS IRIS with steroids, whereas reports of successful treatment of CNS escape usually entail changes in CART based on genotypic analysis of CSF viral sensitivity or by substitution or addition of agents thought to have good CNS drug penetration. Of note, the pathogenesis of CNS IRIS and CNS escape may be similar. Lescure and colleagues (168) describe 14 HIV-infected patients who were initially diagnosed with encephalitis of unknown etiology. Two patients had CNS IRIS, two had CNS escape, one had viral rebound after stopping CART, and six had a minor infection a few days before onset of their neurologic illness. Brain MRI showed diffuse T2 and fluid-attenuated inversion recovery (FLAIR) signal intensities in gray and white matter with punctate or linear gadolinium enhancement that was best seen with T1-weighted spin-echo sequences combined with magnetization transfer. Histology showed intense perivascular infiltration of polyclonal CD8+ lymphocytes.
SPINAL CORD DISEASE
HIV-Associated Myelopathy
Several processes can affect the spinal cord in HIV-infected patients (Table 19.3). HIV-associated myelopathy (HAM) is likely the most common cause of spinal cord dysfunction in this population in the U.S. Most of what we know about the disorder comes from studies conducted before the advent of CART, and the overall incidence of the disease is now low.
Etiology
The pathogenesis of HAM, pathologically termed vacuolar myelopathy, is poorly understood. Detection of HIV in spinal cord is not associated with presence or severity of vacuolar changes (169). Activated macrophages can be identified in the posterior and lateral columns of spinal cords from HIV-infected individuals with and without vacuolar myelopathy (170), and degree of myelin damage is proportional to the number of infiltrating macrophages (171). Thus, the pathogenesis of HAM may be similar to that proposed for HAD. Because of pathologic similarities between HAM and myelopathy associated with vitamin B12 or cobalamin deficiency, nutritional or vitamin deficiencies have also been suggested as a cause of HAM. In autopsy-based series, vitamin B12 levels in patients with vacuolar myelopathy are not low (170,172). However, cobalamin is a cofactor for conversion of homocysteine to methionine, which is subsequently converted to S-adenosylmethionine (SAM). SAM is needed for myelin formation and repair. In a small study, CSF SAM levels were significantly lower in patients with HAM compared to HIV-infected patients without myelopathy and normal controls (173). These results support the hypothesis that HAM may be due to abnormalities of a B12-dependent metabolic pathway.
Differential Diagnosis
Differential diagnosis of myelopathy in HIV-infected patients includes extrinsic cord compression from tumor such as lymphoma, infection, such as bacterial or mycobacterial osteomyelitis, or hemorrhage (174). These entities usually have a rapid course and associated back pain and sensory level, which are uncharacteristic of HAM (see the following discussion). Intrinsic cord abnormalities due to tumor or abscess, particularly lymphoma, toxoplasmosis, or tuberculosis, should also be excluded. Human T-lymphotropic virus (HTLV) type 1 or type 2 infection may be indistinguishable from HAM. Myelitis due to syphilis or herpes viruses (varicella-zoster virus [VZV], herpes simplex virus [HSV], or CMV) and nutritional disorders should also be considered (Table 19.3).
Clinical Findings
Patients with HAM complain of slowly progressive lower extremity weakness and stiffness, trouble walking, and urinary frequency and incontinence. Men may note erectile dysfunction. HAM typically coexists with distal sensory peripheral neuropathy, with concomitant complaints of lower extremity numbness, pain, or dysesthesia (175). Neurologic examination shows spastic paraparesis or paraplegia; gait dysfunction; sensory ataxia; hyperreflexia, often with absent ankle reflexes in the setting of concomitant neuropathy; impaired vibration and position senses; extensor-plantar responses; and sphincter dysfunction (172,175).
Laboratory and Imaging Studies
HAM is a diagnosis of exclusion. MRI of the spinal cord should be undertaken to exclude extrinsic or intrinsic cord lesions. In HAM, MRI is usually normal. When abnormalities are seen, they typically involve the thoracic spinal cord with or without involvement of the cervical cord and include atrophy or increased intramedullary signal intensity (176,177). Abnormal tibial somatosensory-evoked potentials with prolonged conduction time are considered by some to be diagnostic (173). Analysis of CSF is indicated to exclude alternative diagnoses; in HAM, the CSF is typically acellular with mild to moderate elevation in protein concentration (175). One study showed that CSF HIV-1 RNA concentrations were not increased in patients with HAM; however, these individuals were all on stable antiretroviral therapy (178).
Treatment and Prevention
There is no proven treatment for HAM. Case reports describe improvement after beginning CART (179–182), and this is currently the therapy of choice. A controlled trial of L-methionine (183) and an open-label study of IV immunoglobulin for HAM showed no benefit (184). The association between advanced HIV disease and HAM suggests that earlier treatment for HIV is the best preventative strategy.
References
1. Marra CM, Maxwell CL, Collier AC, et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis. 2007;7:37.
2. Dore GJ, Correll PK, Li Y, et al. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13(10): 1249–1253.
3. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology. 2001;56(2):257–260.
4. Vivithanaporn P, Heo G, Gamble J, et al. Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology. 2010;75(13):1150–1158.
5. So YT, Beckstead JH, Davis RL. Primary central nervous system lymphoma in acquired immune deficiency syndrome: a clinical and pathological study. Ann Neurol. 1986;20(5):566–572.
6. Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer. 2001;37(10):1209–1216.
7. Lowenthal DA, Straus DJ, Campbell SW, et al. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer. 1988;61(11):2325–2337.
8. Remick SC, Diamond C, Migliozzi JA, et al. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature. Medicine. 1990;69(6):345–360.
9. Pluda JM, Venzon DJ, Tosato G, et al. Parameters affecting the development of non-Hodgkin’s lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol. 1993;11(6):1099–1107.
10. Goldstein JD, Zeifer B, Chao C, et al. CT appearance of primary CNS lymphoma in patients with acquired immunodeficiency syndrome. J Comput Assist Tomogr. 1991;15(1):39–44.
11. Ruiz A, Ganz WI, Post MJ, et al. Use of thallium-201 brain SPECT to differentiate cerebral lymphoma from toxoplasma encephalitis in AIDS patients. AJNR Am J Neuroradiol. 1994;15(10):1885–1894.
12. Lorberboym M, Wallach F, Estok L, et al. Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients. J Nucl Med. 1998;39(8):1366–1369.
13. Antinori A, Ammassari A, De Luca A, et al. Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology. 1997;48(3):687–694.
14. Ivers LC, Kim AY, Sax PE. Predictive value of polymerase chain reaction of cerebrospinal fluid for detection of Epstein-Barr virus to establish the diagnosis of HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2004;38(11):1629–1632.
15. Corcoran C, Rebe K, van der Plas H, et al. The predictive value of cerebrospinal fluid Epstein-Barr viral load as a marker of primary central nervous system lymphoma in HIV-infected persons. J Clin Virol. 2008;42(4):433–436.
16. Baumgartner JE, Rachlin JR, Beckstead JH, et al. Primary central nervous system lymphomas: natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg. 1990;73(2):206–211.
17. Corn BW, Donahue BR, Rosenstock JG, et al. Performance status and age as independent predictors of survival among AIDS patients with primary CNS lymphoma: a multivariate analysis of a multi-institutional experience. Cancer J Sci Am. 1997;3(1):52–56.
18. Newell ME, Hoy JF, Cooper SG, et al. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004;100(12):2627–2636.
19. Nagai H, Odawara T, Ajisawa A, et al. Whole brain radiation alone produces favourable outcomes for AIDS-related primary central nervous system lymphoma in the HAART era. Eur J Haematol. 2010;84(6):499–505.
20. Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003;17(12):1787–1793.
21. Hoffmann C, Tabrizian S, Wolf E, et al. Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery. AIDS. 2001;15(16):2119–2127.
22. McGowan JP, Shah S. Long-term remission of AIDS-related primary central nervous system lymphoma associated with highly active antiretroviral therapy. AIDS. 1998;12(8):952–954.
23. Aboulafia DM, Puswella AL. Highly active antiretroviral therapy as the sole treatment for AIDS-related primary central nervous system lymphoma: a case report with implications for treatment. AIDS Patient Care STDS. 2007;21(12):900–907.
24. Travi G, Ferreri AJ, Cinque P, et al. Long-term remission of HIV-associated primary CNS lymphoma achieved with highly active antiretroviral therapy alone. J Clin Oncol. 2012;30(10):e119–e121.
25. Raez L, Cabral L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses. 1999;15(8):713–719.
26. Slobod KS, Taylor GH, Sandlund JT, et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet. 2000;356(9240):1493–1494.
27. Aboulafia DM. Interleukin-2, ganciclovir, and high-dose zidovudine for the treatment of AIDS-associated primary central nervous system lymphoma. Clin Infect Dis. 2002;34(12):1660–1662.
28. Bossolasco S, Falk KI, Ponzoni M, et al. Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis. 2006;42(4):e21–e25.
29. Aboulafia DM, Ratner L, Miles SA, et al. Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma. 2006;6(5):399–402.
30. Marretta L, Stocker H, Drauz D, et al. Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res. 2011;16(5):197–205.
31. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001;98(12):3406–3412.
32. Bower M, Powles T, Nelson M, et al. Highly active antiretroviral therapy and human immunodeficiency virus-associated primary cerebral lymphoma. J Natl Cancer Inst. 2006;98(15):1088–1091.
33. Kreisl TN, Panageas KS, Elkin EB, et al. Treatment patterns and prognosis in patients with human immunodeficiency virus and primary central system lymphoma. Leuk Lymphoma. 2008;49(9):1710–1716.
34. Levy RM, Bredesen DE, Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. J Neurosurg. 1985;62(4):475–495.
35. Holland NR, Power C, Mathews VP, et al. Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology. 1994;44(3, pt 1): 507–514.
36. Kriegstein AR, Shungu DC, Millar WS, et al. Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (“chasing the dragon”). Neurology. 1999;53(8):1765–1773.
37. Langford TD, Letendre SL, Marcotte TD, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16(7):1019–1029.
38. Rackstraw S, Meadway J, Bingham J, et al. An emerging severe leukoencephalopathy: is it due to HIV disease or highly active antiretroviral therapy? Int J STD AIDS. 2006;17(3):205–207.
39. Costello DJ, Gonzalez RG, Frosch MP. Case records of the Massachusetts General Hospital. Case 18-2011. A 35-year-old HIV-positive woman with headache and altered mental status. N Engl J Med. 2011;364(24):2343–2352.
40. Zaffiri L, Verma R, Struzzieri K, et al. Immune reconstitution inflammatory syndrome involving the central nervous system in a patient with HIV infection: a case report and review of literature. New Microbiol. 2013;36(1):89–92.
41. Venkataramana A, Pardo CA, McArthur JC, et al. Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology. 2006;67(3):383–388.
42. Berger JR, Kaszovitz B, Post MJ, et al. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection: a review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107(1):78–87.
43. Berger JR, Pall L, Lanska D, et al. Progressive multifocal leukoencephalopathy in patients with HIV infection. J Neurovirol. 1998;4(1):59–68.
44. Koralnik IJ, Wuthrich C, Dang X, et al. JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy. Ann Neurol. 2005;57(4):576–580.
45. Wuthrich C, Dang X, Westmoreland S, et al. Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons. Ann Neurol. 2009;65(6):742–748.
46. Mascarello M, Lanzafame M, Lattuada E, et al. Progressive multifocal leukoencephalopathy in an HIV patient receiving successful long-term HAART. J Neurovirol. 2011;17(2):196–199.
47. Manfredi R, Piergentili B, Marinacci G, et al. Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies. Int J STD AIDS. 2012;23(3):e35–e38.
48. Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36(8):1047–1052.
49. Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–1438.
50. Marzocchetti A, Di Giambenedetto S, Cingolani A, et al. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol. 2005;43(8):4175–4177.
51. Engsig FN, Hansen AB, Omland LH, et al. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis. 2009;199(1):77–83.
52. Khanna N, Elzi L, Mueller NJ, et al. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. Clin Infect Dis. 2009;48(10):1459–1466.
53. Falco V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008;49(1):26–31.
54. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team. AJNR Am J Neuroradiol. 1999;20(10):1896–1906.
55. Lima MA, Bernal-Cano F, Clifford DB, et al. Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry. 2010;81(11):1288–1291.
56. Piza F, Fink MC, Nogueira GS, et al. JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome. Braz J Infect Dis. 2012;16(2):153–156.
57. Marra CM, Rajicic N, Barker DE, et al. A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16(13):1791–1797.
58. Berger JR, Levy RM, Flomenhoft D, et al. Predictive factors for prolonged survival in acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. Ann Neurol. 1998;44(3):341–349.
59. Bossolasco S, Calori G, Moretti F, et al. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis. 2005;40(5):738–744.
60. Gasnault J, Costagliola D, Hendel-Chavez H, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PloS One. 2011;6(6):e20967.
61. Yiannoutsos CT, Major EO, Curfman B, et al. Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy. Ann Neurol. 1999;45(6):816–821.
62. Garcia De Viedma D, Diaz Infantes M, Miralles P, et al. JC virus load in progressive multifocal leukoencephalopathy: analysis of the correlation between the viral burden in cerebrospinal fluid, patient survival, and the volume of neurological lesions. Clin Infect Dis. 2002;34(12):1568–1575.
63. De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis. 2000;182(4):1077–1083.
64. Clifford DB, Nath A, Cinque P, et al. A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol. 2013;19(4):351–318.
65. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004;127(pt 9):1970–1978.
66. Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009; 73(19):1551–1558.
67. Khanna N, Wolbers M, Mueller NJ, et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol. 2009;83(9):4404–4411.
68. Dworkin MS, Wan PC, Hanson DL, et al. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis. 1999;180(3):621–625.
69. Fanjul F, Riveiro-Barciela M, Gonzalez J, et al. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? HIV Med. 2013;14(5):321–325.
70. Clifford DB, Yiannoutsos C, Glicksman M, et al. HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology. 1999;52(3):623–625.
71. Gasnault J, Taoufik Y, Goujard C, et al. Prolonged survival without neurological improvement in patients with AIDS-related progressive multifocal leukoencephalopathy on potent combined antiretroviral therapy. J Neurovirol. 1999;5(4):421–429.
72. De Luca A, Ammassari A, Pezzotti P, et al. Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 2008;22(14):1759–1767.
73. Tan K, Roda R, Ostrow L, et al. PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids. Neurology. 2009;72(17):1458–1464.
74. Harrison DM, Newsome SD, Skolasky RL, et al. Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol. 2011;238(1-2):81–86.
75. Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis. 2002;35(10):1250–1257.
76. Hoffmann C, Horst HA, Albrecht H, et al. Progressive multifocal leucoencephalopathy with unusual inflammatory response during antiretroviral treatment. J Neurol Neurosurg Psychiatry. 2003;74(8):1142–1144.
77. D’Amico R, Sarkar S, Yusuff J, et al. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis. 2007;39(4):347–350.
78. Martinez JV, Mazziotti JV, Efron ED, et al. Immune reconstitution inflammatory syndrome associated with PML in AIDS: a treatable disorder. Neurology. 2006;67(9):1692–1694.
79. Martin-Blondel G, Cuzin L, Delobel P, et al. Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? AIDS. 2009;23(18):2545–2546.
80. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338(19):1345–1351.
81. Brickelmaier M, Lugovskoy A, Kartikeyan R, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother. 2009;53(5):1840–1849.
82. Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380–1383.
83. Cettomai D, McArthur JC. Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy. Arch Neurol. 2009;66(2):255–258.
84. Lanzafame M, Ferrari S, Lattuada E, et al. Mirtazapine in an HIV-1 infected patient with progressive multifocal leukoencephalopathy. Le Infezioni in Medicina. 2009;17(1):35–37.
85. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19(6):517–524.
86. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–1799.
87. Price RW, Brew B, Sidtis J, et al. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239(4840):586–592.
88. Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11(1):39–44.
89. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology. 1993;43(11):2245–2252.
90. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–2096.
91. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24(9):1243–1250.
92. Bonnet F, Amieva H, Marquant F, et al. Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS. 2013;27(3):391–400.
93. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis. 2011;11:356.
94. Torti C, Foca E, Cesana BM, et al. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med. 2011;9:138.
95. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915–1921.
96. McArthur JC. HIV dementia: an evolving disease. J Neuroimmunol. 2004;157(1–2):3–10.
97. Woods SP, Moore DJ, Weber E, et al. Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev. 2009;19(2): 152–168.
98. Munoz-Moreno JA, Fumaz CR, et al. Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retroviruses. 2008;24(10):1301–1307.
99. Ellis RJ, Badiee J, Vaida F, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747–1751.
100. Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213–221.
101. McCombe JA, Vivithanaporn P, Gill MJ, et al. Predictors of symptomatic HIV-associated neurocognitive disorders in universal health care. HIV Med. 2013;14(2):99–107.
102. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125(4):257–264.
103. Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology. 1992;42(9):1736–1739.
104. Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis. 1997;24(5):965–970.
105. del Saz SV, Sued O, Falco V, et al. Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol. 2008;14(6):474–479.
106. Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology. 2012;79(24):2328–2334.
107. Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275–282.
108. Peluso MJ, Meyerhoff DJ, Price RW, et al. Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis. 2013;207(11):1703–1712.
109. Burdo TH, Lackner A, Williams KC. Monocyte/macrophages and their role in HIV neuropathogenesis. Immunol Rev. 2013;254(1):102–113.
110. Ancuta P, Kamat A, Kunstman KJ, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PloS One. 2008;3(6):e2516.
111. Ellery PJ, Tippett E, Chiu YL, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007;178(10):6581–6589.
112. Kusao I, Shiramizu B, Liang CY, et al. Cognitive performance related to HIV-1-infected monocytes. J Neuropsychiatry Clin Neurosci. 2012;24(1):71–80.
113. Wesselingh SL, Thompson KA. Immunopathogenesis of HIV-associated dementia. Curr Opin Neurol. 2001;14(3):375–379.
114. Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat Rev Immunol. 2005;5(1):69–81.
115. Lindl KA, Marks DR, Kolson DL, et al. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J Neuroimmune Pharmacol. 2010;5(3):294–309.
116. Spudich S, Gonzalez-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med. 2012;2(6):a007120.
117. Glass JD, Fedor H, Wesselingh SL, et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol. 1995;38(5):755–762.
118. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol. 2009;15(5–6):360–370.
119. Wendelken LA, Valcour V. Impact of HIV and aging on neuropsychological function. J Neurovirol. 2012;18(4):256–263.
120. Becker JT, Kingsley L, Mullen J, et al. Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men. Neurology. 2009;73(16):1292–1299.
121. Foley J, Ettenhofer M, Wright MJ, et al. Neurocognitive functioning in HIV-1 infection: effects of cerebrovascular risk factors and age. Clin Neuropsychol. 2010;24(2):265–285.
122. Wright EJ, Grund B, Robertson K, Brew BJ, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology. 2010;75(10):864–873.
123. McCutchan JA, Marquie-Beck JA, Fitzsimons CA, et al. Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder. Neurology. 2012;78(7):485–492.
124. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23(11):1359–1366.
125. Robertson KR, Su Z, Margolis DM, et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology. 2010;74(16):1260–1266.
126. Ciccarelli N, Fabbiani M, Di Giambenedetto S, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology. 2011;76(16):1403–1409.
127. Zunt JR, Tu RK, Anderson DM, et al. Progressive multifocal leukoencephalopathy presenting as human immunodeficiency virus type 1 (HIV)-associated dementia. Neurology. 1997;49(1):263–265.
128. Sidtis JJ, Price RW. Early HIV-1 infection and the AIDS dementia complex [comment]. Neurology. 1990;40(2):323–326.
129. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis. 1988;158(5):1079–1083.
130. McArthur JC, Nance-Sproson TE, Griffin DE, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2- microglobulin in HIV-1 dementia. Multicenter AIDS Cohort Study. Neurology. 1992;42(9):1707–1712.
131. Ellis RJ, Hsia K, Spector SA, et al. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol. 1997;42(5):679–688.
132. Brew BJ, Pemberton L, Cunningham P, et al. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis. 1997;175(4):963–966.
133. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol. 1997;42(5):689–698.
134. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol. 2002;59(6):923–928.
135. McArthur JC, McDermott MP, McClernon D, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol. 2004;61(11):1687–1696.
136. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirology. 2011;17(1):3–16.
137. Cohen WA, Maravilla KR, Gerlach R, et al. Prospective cerebral MR study of HIV seropositive and seronegative men: correlation of MR findings with neurologic, neuropsychologic, and cerebrospinal fluid analysis. AJNR Am J Neuroradiol. 1992;13(4):1231–1240.
138. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo- controlled trial. AIDS Clinical Trials Group. Ann Neurol. 1993;33(4):343–349.
139. Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS. 1993;7(5):669–675.
140. Staprans S, Marlowe N, Glidden D, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13(9):1051–1061.
141. Sacktor NC, Lyles RH, Skolasky RL, et al. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS). Neurology. 1999;52(8):1640–1647.
142. Sacktor NC, Skolasky RL, Lyles RH, et al. Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors. J Neurovirol. 2000;6(1):84–88.
143. Dore GJ, McDonald A, Li Y, et al. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 2003;17(10):1539–1545.
144. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73(5):342–348.
145. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology. 2013;80(4):371–379.
146. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70.
147. Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med. 2011;19(4): 137–142.
148. Cysique LA, Waters EK, Brew BJ. Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurology. 2011;11:148.
149. Ciccarelli N, Fabbiani M, Colafigli M, et al. Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia. Antivir Ther. 2013;18(2):153–160.
150. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis. 2010;50(6):920–929.
151. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther. 2012;17(7):1233–1242.
152. Price RW, Swanstrom R. Targeting chronic central nervous system HIV infection. Antivir Ther. 2012;17(7):1227–1231.
153. Navia BA, Dafni U, Simpson D, et al. A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology. 1998;51(1):221–228.
154. Clifford DB, McArthur JC, Schifitto G, et al. A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology. 2002;59(10):1568–1573.
155. Schifitto G, Yiannoutsos CT, Ernst T, et al. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009;73(23):1975–1981.
156. Schifitto G, Zhang J, Evans SR, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology. 2007;69(13):1314–1321.
157. Schifitto G, Navia BA, Yiannoutsos CT, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS. 2007;21(14):1877–1886.
158. Zhao Y, Navia BA, Marra CM, et al. Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials. 2010;11(1):59–67.
159. Ho EL, Spudich SS, Lee E, et al. Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot study. AIDS Res Ther. 2011;8:17.
160. Nakasujja N, Miyahara S, Evans S, et al. Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. Neurology. 2013;80(2):196–202.
161. Sacktor N, Miyahara S, Deng L, et al. Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial. Neurology. 2011;77(12):1135–1142.
162. Simioni S, Cavassini M, Annoni JM, et al. Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study. Neurology. 2013;80(6):553–560.
163. Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis. 2003;37(8):1107–1011.
164. Mehling M, Drechsler H, Kuhle J, et al. Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement. J Neurovirol. 2008;14(1):78–84.
165. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect. 2011;63(3):236–239.
166. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis. 2010;50(5):773–778.
167. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–1825.
168. Lescure FX, Moulignier A, Savatovsky J, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis. 2013;57(1):101–108.
169. Rosenblum M, Scheck AC, Cronin K, et al. Dissociation of AIDS-related vacuolar myelopathy and productive HIV-1 infection of the spinal cord. Neurology. 1989;39(7):892–896.
170. Tyor WR, Glass JD, Baumrind N, et al. Cytokine expression of macrophages in HIV-1-associated vacuolar myelopathy. Neurology. 1993; 43(5):1002–1009.
171. Eilbott DJ, Peress N, Burger H, et al. Human immunodeficiency virus type 1 in spinal cords of acquired immunodeficiency syndrome patients with myelopathy: expression and replication in macrophages. Proc Natl Acad Sci U S A. 1989;86(9):3337–3341.
172. Petito CK, Navia BA, Cho ES, et al. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1985;312(14):874–879.
173. Di Rocco A, Bottiglieri T, Werner P, et al. Abnormal cobalamin-dependent transmethylation in AIDS-associated myelopathy. Neurology. 2002;58(5):730–735.
174. Modi G, Ranchhod J, Hari K, et al. Non-traumatic myelopathy at the Chris Hani Baragwanath Hospital, South Africa—the influence of HIV. QJM. 2011;104(8):697–703.
175. Dal Pan GJ, Glass JD, McArthur JC. Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology. 1994;44(11):2159–64.
176. Chong J, Di Rocco A, Tagliati M, et al. MR findings in AIDS-associated myelopathy. AJNR Am J Neuroradiol. 1999;20(8):1412–1416.
177. Shimojima Y, Yazaki M, Kaneko K, et al. Characteristic spinal MRI findings of HIV-associated myelopathy in an AIDS patient. Intern Med. 2005;44(7):763–764.
178. Geraci A, Di Rocco A, Liu M, et al. AIDS myelopathy is not associated with elevated HIV viral load in cerebrospinal fluid. Neurology. 2000;55(3):440–442.
179. Bizaare M, Dawood H, Moodley A. Vacuolar myelopathy: a case report of functional, clinical, and radiological improvement after highly active antiretroviral therapy. Int J Infect Dis. 2008;12(4):442–444.
180. Staudinger R, Henry K. Remission of HIV myelopathy after highly active antiretroviral therapy. Neurology. 2000;54(1):267–268.
181. Fernandez-Fernandez FJ, de la Fuente-Aguado J, Ocampo-Hermida A, et al. Remission of HIV-associated myelopathy after highly active antiretroviral therapy. J Postgrad Med. 2004;50(3):195–196.
182. Eyer-Silva WA, Couto-Fernandez JC, Caetano MR, et al. Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy. AIDS. 2002;16(17):2367–2369.
183. Di Rocco A, Werner P, Bottiglieri T, et al. Treatment of AIDS-associated myelopathy with L-methionine: a placebo-controlled study. Neurology. 2004;63(7):1270–1275.
184. Cikurel K, Schiff L, Simpson DM. Pilot study of intravenous immunoglobulin in HIV-associated myelopathy. AIDS Patient Care STDS. 2009;23(2):75–78.